Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleTheranostics

68Ga-Pentixafor PET/CT for Imaging of Chemokine Receptor 4 Expression in Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT

Yaping Luo, Xinxin Cao, Qingqing Pan, Jian Li, Jun Feng and Fang Li
Journal of Nuclear Medicine December 2019, 60 (12) 1724-1729; DOI: https://doi.org/10.2967/jnumed.119.226134
Yaping Luo
1Department of Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing, People’s Republic of China
2Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, People’s Republic of China; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xinxin Cao
3Department of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing, People’s Republic of China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qingqing Pan
1Department of Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing, People’s Republic of China
2Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, People’s Republic of China; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jian Li
3Department of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing, People’s Republic of China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Feng
3Department of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing, People’s Republic of China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fang Li
1Department of Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing, People’s Republic of China
2Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, People’s Republic of China; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 60 no. 12 1724-1729
DOI 
https://doi.org/10.2967/jnumed.119.226134
PubMed 
31101745

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication January 27, 2019
  • Accepted for publication May 7, 2019
  • Published online December 2, 2019.

Article Versions

  • previous version (May 17, 2019 - 14:01).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Yaping Luo*,1,2,
  2. Xinxin Cao*,3,
  3. Qingqing Pan1,2,
  4. Jian Li3,
  5. Jun Feng3 and
  6. Fang Li1,2
  1. 1Department of Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing, People’s Republic of China
  2. 2Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, People’s Republic of China; and
  3. 3Department of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing, People’s Republic of China
  1. For correspondence or reprints contact: Fang Li, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Wangfujing, Dongcheng District, Beijing 100730, People’s Republic of China. E-mail: lifang{at}pumch.cn
  1. ↵* Contributed equally to this work.

View Full Text

Statistics from Altmetric.com

Cited By...

  • 53 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • CXCR4-targeted theranostics in oncology
    Andreas K. Buck, Sebastian E. Serfling, Thomas Lindner, Heribert Hänscheid, Andreas Schirbel, Stefanie Hahner, Martin Fassnacht, Hermann Einsele, Rudolf A. Werner
    European Journal of Nuclear Medicine and Molecular Imaging 2022 49 12
  • Chemokine receptor-4 targeted PET/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET/CT
    Qingqing Pan, Xinxin Cao, Yaping Luo, Jian Li, Jun Feng, Fang Li
    European Journal of Nuclear Medicine and Molecular Imaging 2020 47 3
  • Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
    Johannes Duell, Franziska Krummenast, Andreas Schirbel, Philipp Klassen, Samuel Samnick, Hilka Rauert-Wunderlich, Leo Rasche, Andreas K. Buck, Hans-Jürgen Wester, Andreas Rosenwald, Herrmann Einsele, Max S. Topp, Constantin Lapa, Malte Kircher
    Journal of Nuclear Medicine 2021 62 10
  • CXCR4 PET/MRI for follow-up of gastric mucosa–associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication
    Marius E. Mayerhoefer, Markus Raderer, Wolfgang Lamm, Michael Weber, Barbara Kiesewetter, Johannes Rohrbeck, Ingrid Simonitsch-Klupp, Marcus Hacker, Asha Leisser, Lukas Nics, Stefan Schmitl, Hans-Juergen Wester, Alexander Haug
    Blood 2022 139 2
  • In Vivo Targeting of CXCR4—New Horizons
    Margret Schottelius, Ken Herrmann, Constantin Lapa
    Cancers 2021 13 23
  • FDG-PET/CT in Lymphoma: Where Do We Go Now?
    Yassine Al Tabaa, Clement Bailly, Salim Kanoun
    Cancers 2021 13 20
  • Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [68Ga]pentixafor in non-Hodgkin lymphoma: comparison to [18F]FDG
    Qingqing Pan, Yaping Luo, Yan Zhang, Long Chang, Ji Li, Xinxin Cao, Jian Li, Fang Li
    EJNMMI Research 2020 10 1
  • High-Contrast CXCR4-Targeted 18F-PET Imaging Using a Potent and Selective Antagonist
    Daniel Kwon, Jerome Lozada, Zhengxing Zhang, Jutta Zeisler, Richel Poon, Chengcheng Zhang, Áron Roxin, Kuo-Shyan Lin, David Perrin, Francois Benard
    Molecular Pharmaceutics 2021 18 1
  • Advances in PET Imaging of the CXCR4 Receptor: [68Ga]Ga-PentixaFor
    Liza Lindenberg, Mark Ahlman, Frank Lin, Esther Mena, Peter Choyke
    Seminars in Nuclear Medicine 2024 54 1
  • FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects
    Akram Al-Ibraheem, Ahmed Saad Abdlkadir, Malik E. Juweid, Kamal Al-Rabi, Mohammad Ma’koseh, Hikmat Abdel-Razeq, Asem Mansour
    Cancers 2023 15 4

Article usage

Article usage: May 2019 to April 2025

AbstractFullPdf
May 2019426027
Jun 2019221016
Jul 2019151013
Aug 20197805
Sep 20193703
Oct 20196109
Nov 201960010
Dec 201912301599
Jan 2020308826
Feb 20201521017
Mar 202010668
Apr 20206228
May 20207313
Jun 2020691225
Jul 2020521014
Aug 202039620
Sep 202034152
Oct 2020422517
Nov 20204269
Dec 202040618
Jan 2021183217
Feb 2021173615
Mar 2021233229
Apr 2021174123
May 2021193321
Jun 202110226
Jul 2021142925
Aug 202173717
Sep 2021182113
Oct 2021151525
Nov 2021112525
Dec 202172812
Jan 2022142816
Feb 2022181810
Mar 202231510
Apr 2022112413
May 202271918
Jun 202281312
Jul 202253215
Aug 202271610
Sep 202292818
Oct 202241515
Nov 2022132223
Dec 202242411
Jan 202313326
Feb 20236238
Mar 202373515
Apr 202322189
May 2023202919
Jun 202372212
Jul 202362616
Aug 20237239
Sep 2023102313
Oct 2023103626
Nov 202393722
Dec 202363422
Jan 2024122915
Feb 20243178
Mar 202422994
Apr 202448729
May 202455819
Jun 2024122515
Jul 202483323
Aug 202484221
Sep 202423220
Oct 2024114120
Nov 202454317
Dec 202475516
Jan 202535016
Feb 202587427
Mar 202535224
Apr 2025135122
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 60 (12)
Journal of Nuclear Medicine
Vol. 60, Issue 12
December 1, 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
68Ga-Pentixafor PET/CT for Imaging of Chemokine Receptor 4 Expression in Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
68Ga-Pentixafor PET/CT for Imaging of Chemokine Receptor 4 Expression in Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT
Yaping Luo, Xinxin Cao, Qingqing Pan, Jian Li, Jun Feng, Fang Li
Journal of Nuclear Medicine Dec 2019, 60 (12) 1724-1729; DOI: 10.2967/jnumed.119.226134

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
68Ga-Pentixafor PET/CT for Imaging of Chemokine Receptor 4 Expression in Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT
Yaping Luo, Xinxin Cao, Qingqing Pan, Jian Li, Jun Feng, Fang Li
Journal of Nuclear Medicine Dec 2019, 60 (12) 1724-1729; DOI: 10.2967/jnumed.119.226134
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • KEY POINTS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Molecular Imaging of Cancer Stem Cells and Their Role in Therapy Resistance
  • Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
  • Google Scholar

More in this TOC Section

Theranostics

  • Determination of the Intralesional Distribution of Theranostic 124I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma
  • Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
  • 177Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer
Show more Theranostics

Clinical

  • Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
  • SUVs Are Adequate Measures of Lesional 18F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden
  • Hypermetabolism on Pediatric PET Scans of Brain Glucose Metabolism: What Does It Signify?
Show more Clinical

Similar Articles

Keywords

  • Waldenström macroglobulinemia
  • lymphoplasmacytic lymphoma
  • CXCR4
  • 68Ga-pentixafor
  • PET/CT
SNMMI

© 2025 SNMMI

Powered by HighWire